Biodesix to highlight novel diagnostic test discovery and pipeline development at AACR 2026
Biodesix, Inc. to present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) Annual Meeting
20 Apr 2026
Biodesix, Inc. will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, USA. The presentations demonstrated Biodesix capabilities in blood-and tissue-based testing and monitoring across a range of applications.
Tumor and immune profiling expertise
Biodesix oral and poster presentations highlight diverse technology platforms, rapid turn-around times for clinical tests, and extensive capabilities in immune and tumor profiling using mass spectrometry, Bio-Rad Droplet Digital PCR™, and Thermo Scientific™ Ion AmpliSeq™ platforms.
In addition, Biodesix has validated a new clinical myeloid panel on the Thermo Scientific™ Ion Torrent™ Genexus™ System. The platform supports an automated clinical next-generation sequencing (NGS) workflow and can deliver sequencing results in as little as 24 hours.
Molecular residual disease (MRD) product pipeline
Another set of presentations will highlight a novel, multi-omic approach to MRD monitoring. Thermo Fisher Scientific, Bio-Rad Laboratories, and Memorial Sloan Kettering Cancer Center will co-present new data on proteomic and genomic biomarkers as well as bioinformatics workflows central to the Biodesix MRD pipeline tests.
Dr. Gary Pestano, Chief Scientific Officer, Biodesix, said, “Biodesix expertise in test discovery and development, regulatory, reimbursement, and commercialization provides an exceptional level of service for our partners across a range of applications. The AACR presentations showcase basic research through clinical applications and pre-validated assays available for biopharma and life science partners, as well as advancements in our pipeline efforts. The data are reinforced by more than a decade of experience supporting the clinical development and commercialization of new diagnostics and therapeutics.”